HK Stock Market Move | EVEREST MED(01952) Surges Over 5% in Early Trading; Company Appoints Two Moderna Oncology Vaccine Scientists to Accelerate Global mRNA Clinical Trials

EVEREST MED(01952) surged over 5% in early trading. As of press time, it rose 1.60% to HK$29.26, with a turnover of HK$20.5006 million. On the news front, on October 9, EVEREST MED announced the appointment of Dr. Lakshmi Srinivasan as Senior Vice President and Head of Translational Medicine, and Dr. Brandon Coder as Vice President of Translational Science and Early Research. Both new executives possess deep industry experience and professional backgrounds, having previously been responsible for oncology vaccine R&D at globally leading biopharmaceutical companies such as Moderna, with complete hands-on experience spanning from early discovery to clinical translation and clinical development. This major talent recruitment is a key move by EVEREST MED to accelerate its global mRNA strategy, and will further strengthen the global R&D capabilities and international collaboration layout of EVEREST MED's mRNA technology platform. Under the leadership of EVEREST MED's management, the two scientists will focus on advancing the clinical development of EVEREST MED's mRNA technology platform in the United States and related business layout, and will work closely with the China R&D team to further empower the evolution of the mRNA technology platform.